Ponezumab
Ponezumab is a monoclonal antibody designed for the treatment of Alzheimer's disease. It was developed by Pfizer and is currently in the clinical trial phase. Ponezumab targets amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients.
History[edit]
Ponezumab was first developed by Pfizer in the early 2000s. The drug entered Phase I clinical trials in 2005, and Phase II trials in 2008. In 2012, Pfizer announced that Ponezumab had failed to meet its primary endpoints in a Phase II trial, but the company continued to investigate its potential for treating Alzheimer's disease.
Mechanism of Action[edit]
Ponezumab is a monoclonal antibody that binds to amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. By binding to amyloid beta, Ponezumab is thought to prevent the formation of these plaques, thereby slowing the progression of Alzheimer's disease.
Clinical Trials[edit]
Ponezumab has undergone several clinical trials to assess its safety and efficacy in treating Alzheimer's disease. In a Phase II trial, Ponezumab failed to meet its primary endpoints, but showed some promise in slowing cognitive decline in patients with mild-to-moderate Alzheimer's disease. Pfizer is currently conducting further trials to investigate the potential of Ponezumab in treating Alzheimer's disease.
See Also[edit]
This WikiMD article can only be edited by registered and verified editors. You can log in or register.
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
